Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

Sunil Pancholi(Institute of Cancer Research), Lesley‐Ann Martin(Institute of Cancer Research)

npj Breast Cancer

November 29, 2022

10.1038/s41523-022-00483-1

Cited by 16

Related Papers

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

|Breast Cancer Research|2012|43

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

|Breast Cancer Research|2012|33

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

|Breast Cancer Research|2014|26